BiotechTube
Moonlight Bio

Moonlight Bio

San Diego, United States· Est.
moonlightbio.us
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

Moonlight Bio is a private, preclinical-stage biotech focused on developing next-generation T cell therapies for cancer by mining evolutionary biology. The company leverages a discovery platform that identifies naturally occurring, potent T cell adaptations within human biology to engineer enhanced cell therapies, primarily targeting solid tumors. Key strategic partnerships with MaxCyte, Kincell Bio, and ZenQMS in 2025-2026 indicate active platform and pipeline advancement. As a young, pre-revenue company, its success hinges on translating its novel evolutionary insights into clinically differentiated and effective therapies.

Oncology

Technology Platform

A discovery platform that identifies and leverages natural T cell adaptations from human evolutionary biology to engineer T cell therapies with enhanced proliferation, persistence, and function for treating cancer.

Funding History

1
Total raised:$4M
Seed$4M

Opportunities

The massive unmet need in solid tumor oncology represents a multi-billion dollar market opportunity for effective cell therapies.
Moonlight's evolution-based discovery platform could yield a pipeline of differentiated therapies and has potential for lucrative platform licensing deals.
Success in the clinic could position the company as a key player in the next generation of cell therapies or an attractive acquisition target.

Risk Factors

High scientific risk that the platform's discoveries will not translate into safe and effective clinical products.
Intense competition in the solid tumor cell therapy space from companies with greater resources.
Significant regulatory and manufacturing hurdles inherent to complex, genetically modified cell therapies.

Competitive Landscape

Moonlight Bio competes in the crowded and rapidly evolving field of next-generation T cell therapies for solid tumors, facing companies like Affini-T, ArsenalBio, and Adaptimmune. Its key differentiator is its foundational hypothesis of mining evolutionary biology rather than relying solely on synthetic engineering. However, it must demonstrate that this approach yields clinically superior products against competitors using CRISPR, logic gates, and other advanced modalities.

More companies in Cell & Gene Therapy →More companies in United States →